Melbourne, 8 May 2012: Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced
receipt of licence fees of US$844,000 under existing licence agreements for its LAIV influenza vaccine. This
brings the total revenue from LAIV licensing to US$1.4 million for the financial year to date.
BioDiem looks forward to being able to meet the growing demand for influenza vaccines in the future through
further licencing of the LAIV influenza vaccine.
“Building the revenue stream from our vaccine licensing work is a key objective for BioDiem, and we are
pleased to announce an increase in these cash flows” said BioDiem Chief Executive Officer Julie Phillips.
“Increasing the availability of the LAIV intranasal vaccine will help increase vaccination uptake, especially in
children, and lower the number of preventable deaths from influenza”.
As well as working to expand its vaccine licensing business, BioDiem continues to advance its product and
technology portfolio with the aim of developing further technologies for the prevention and treatment of other
significant infectious diseases.
About BioDiem Ltd
BioDiem is an ASX-listed company based in Melbourne with an international focus on discovering, developing
and commercialising world-class research and technology for the prevention and treatment of infectious
diseases. BioDiem’s core technologies derive from its expertise with the Live Attenuated Influenza Virus (LAIV),
which is an intranasal vaccine to prevent infection from seasonal and pandemic influenza.
BioDiem is also developing non-LAIV-related assets including BDM-I, a synthetic compound active against a
range of pathogenic micro-organisms including gram-positive and gram-negative bacteria, fungi and protozoa.
Key patents have been filed around BDM-I’s antimicrobial action. BDM-I is being developed for the treatment of
serious human infections with outlicensing as the intended outcome.
About LAIV Technology
The Live Attenuated Influenza Virus (LAIV) vaccine was in-licensed from the Institute of Experimental Medicine
in St Petersburg, Russia, where it has been approved and used in its present form for over a decade in many
millions of people - children, adults and the elderly.
LAIV vaccine is administered by nasal spray and induces a rapid immune response in the mucosal lining of the
nose and pharynx. The vaccines are based on ‘Master Donor Strains’ that have been rendered ‘cold adapted’
and temperature sensitive, such that they will not replicate readily at temperatures above 33?C, as found in the
lungs. The administration of the live vaccine stimulates mucosal, cellular and humoral immune responses (which
are required to optimise the effective prevention of influenza), without causing the disease.
For additional information, please visit www.biodiem.com
Contact
Investors
Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9613 4100
Email jphillips@biodiem.com
Media
Tom Donovan
Buchan Consulting
Phone +61 3 8866 1224 / +61 422 557 107
Email tdonovan@buchanwe.com.au